Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China Apr 16, 2019
Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting Mar 27, 2019
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients Mar 4, 2019
Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium Feb 19, 2019
Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types Feb 4, 2019
